Interactions between endothelin-1 and the renin-angiotensin-aldosterone system

Cardiovascular Research

Volumn 43, Issue 2, 1999, Pages 300-307

  Rossi, Gian Paolo ^a   Sacchetto, Alfredo ^a   Cesari, Maurizio ^a   Pessina, Achille C ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Angiotensin; Endothelins; Hypertension; Receptors; Renin angiotensin system

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ENDOTHELIN 1; RENIN;

ARTICLE; BLOOD PRESSURE REGULATION; GENE CONTROL; HORMONAL REGULATION; HUMAN; HYPERTENSION; JUXTAGLOMERULAR CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TRANSCRIPTION REGULATION; ZONA GLOMERULOSA;

ALDOSTERONE; ANIMALS; ENDOTHELIN-1; HUMANS; HYPERTENSION; MODELS, BIOLOGICAL; PLASMA VOLUME; RECEPTORS, ALDOSTERONE; RECEPTORS, ENDOTHELIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0033178254     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00110-8     Document Type: Article

References (68)

1. Masaki T. Possible role of endothelin in endothelial regulation of vascular tone. Annu Rev Pharmacol Toxicol. 35:1995;235-255.
2. Rubanyi G.M., Botelho L.H. Endothelins. FASEB J. 5:1991;2713-2720.
3. Johnston C.I. Franz Volhard Lecture. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens Suppl. 10:1992;S13-S26.
4. Lee M.E., Bloch K.D., Clifford J.A., Quertermous T. Functional analysis of the endothelin-1 gene promoter: Evidence for an endothelial cell specific cis-acting sequence. J Biol Chem. 265:1990;10446-10450.
5. Dohi Y., Criscione L., Lüscher T.F. Renovascular hypertension impairs formation of endothelium-derived relaxing factors and sensitivity to endothelin-1 in resistance arteries. Br J Pharmacol. 104:1991;349-354.
6. Tschudi M.R., Lüscher T.F. Characterization of contractile endothelin and angiotensin receptors in human resistance arteries: evidence for two endothelin and one angiotensin receptor. Biochem Biophys Res Commun. 204:1994;685-690.
7. Urata H., Kinoshita A., Perez D.M., et al. Cloning of the gene and cDNA for human heart chymase. J Biol Chem. 266:1991;17173-17179.
8. Nakano A., Kishi F., Minami K., et al. Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J Immunol. 159:1997;1987-1992.
9. Kishi F., Minami K., Okishima N., et al. Novel 31-amino-acid-length endothelins cause constriction of vascular smooth muscle. Biochem Biophys Res Commun. 248:1998;387-390.
10. Nussdorfer G.G., Rossi G.P., Belloni A.S. The role of endothelins in the paracrine control of the secretion and growth of the adrenal cortex. Int Rev Cytol. 171:1997;267-308.
11. Rossi G.P., Albertin G., Belloni A., et al. Gene expression, localization, and characterization of endothelin A and B receptors in the human adrenal cortex. J Clin Invest. 94:1994;1226-1234.
12. Hahn A.W., Resink T.J., Scott Burden T., et al. Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Regul. 1:1990;649-659.
13. Resink T.J., Scott-Burden T., Bühler F.R. Endothelin stimulates phospholipase C in cultured vascular smooth muscle cells. Biochem Biophys Res Commun. 157:1988;1360-1368.
14. Sung C.P., Arleth A.J., Storer B.L., Ohlstein E.H. Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle. J Pharmacol Exp Ther. 271:1994;429-437.
15. Imai T., Hirata Y., Emori T., et al. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension. 19:1992;753-757.
16. Chua B.H., Chua C.C., Diglio C.A., Siu B.B. Regulation of endothelin-1 mRNA by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta. 1178:1993;201-206.
17. Ito H., Hirata Y., Adachi S., et al. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest. 92:1993;398-403.
18. Ishiye M., Umemura K., Uematsu T., Nakashima M. Angiotensin AT1 receptor-mediated attenuation of cardiac hypertrophy due to volume overload: involvement of endothelin. Eur J Pharmacol. 280:1995;11-17.
19. Sakai S., Miyauchi T., Kobayashi M., et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 384:1996;353-355.
20. Mulder P., Richard V., Derumeaux G., et al. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 96:1997;1976-1982.
21. Beierwaltes W.H., Carretero O.A. Nonprostanoid endothelium-derived factors inhibit renin release. Hypertension. 19:1992;II68-II73.
22. Moe O., Tejedor A., Campbell W.B., Alpern R.J., Henrich W.L. Effects of endothelin on in vitro renin secretion. Am J Physiol. 260:1991;E521-E525.
23. Ackermann M., Ritthaler T., Riegger G., Kurtz A., Kramer B.K. Endothelin inhibits cAMP-induced renin release from isolated renal juxtaglomerular cells. J Cardiovasc Pharmacol. 26:1995;S135-S137.
24. Kramer B.K., Ritthaler T., Ackermann M., et al. Endothelium-mediated regulation of renin secretion. Kidney Int. 46:1994;1577-1579.
25. Kramer B.K., Schricker K., Scholz H., et al. Role of endothelins for renin regulation. Kidney Int Suppl. 55:1996;S119-S121.
26. Ito S., Juncos L.A., Nushiro N., Johnson C.S., Carretero O.A. Endothelium-derived relaxing factor modulates endothelin action in afferent arterioles. Hypertension. 17:1991;1052-1056.
27. Lin H., Sangmal M., Smith M.J.J., Young D.B. Effect of endothelin-1 on glomerular hydraulic pressure and renin release in dogs. Hypertension. 21:1993;845-851.
28. Polonia J., Ferreira-de-Almeida J., Matias A., et al. Renin-angiotensin-aldosterone, sympathetic and endothelin systems in normal and hypertensive pregnancy: response to postural and volume load stimuli. J Hypertens. 11:(Suppl 5):1993;S242-S243.
29. Koseki C., Imai M., Hirata Y., Yanagisawa M., Masaki T. Autoradiographic distribution in rat tissues of binding sites for endothelin: a neuropeptide? Am J Physiol. 256:1989;R858-R866.
30. Imai T., Hirata Y., Eguchi S., et al. Concomitant expression of receptor subtype and isopeptide of endothelin by human adrenal gland. Biochem Biophys Res Commun. 182:1992;1115-1121.
31. Cozza E.N., Gomez Sanchez C.E., Foecking M.F., Chiou S. Endothelin binding to cultured calf adrenal zona glomerulosa cells and stimulation of aldosterone secretion. J Clin Invest. 84:1989;1032-1035.
32. Cozza E.N., Chiou S., Gomez Sanchez C.E. Endothelin-1 potentiation of angiotensin II stimulation of aldosterone production. Am J Physiol. 262:1992;R85-R89.
33. Gomez Sanchez C.E., Cozza E.N., Foecking M.F., Chiou S., Ferris M.W. Endothelin receptor subtypes and stimulation of aldosterone secretion. Hypertension. 15:1990;744-747.
34. Pecci A., Cozza E.N., Devlin M., Gomez Sanchez C.E., Gomez Sanchez E.P. Endothelin-1 stimulation of aldosterone and zona glomerulosa ouabain-sensitive sodium/potassium-ATPase. J Steroid Biochem Mol Biol. 50:1994;49-53.
35. Pecci A., Gomez Sanchez C.E., de Bedners M.E., Lantos C.P., Cozza E.N. In vivo stimulation of aldosterone biosynthesis by endothelin: loci of action and effects of doses and infusion rate. J Steroid Biochem Mol Biol. 45:1993;555-561.
36. Belloni A., Rossi G.P., Andreis P.G., et al. Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats. Hypertension. 27:1996;1153-1159.
37. B receptor subtypes. J Clin Endocrinol Metab. 82:1997;3445-3449.
38. 2+ in human adrenocortical carcinoma. Endocrinology. 138:1997;4421-4426.
39. Mathieu M.N., Hamroun D., Pouzeratte Y., et al. Adrenal steroid-secreting cells express endothelin-1. Endocr Res. 24:1998;743-747.
40. Mazzocchi G., Rossi G.P., Rebuffat P., et al. Endothelin-1 stimulates deoxyribonucleic acid synthesis and cell proliferation in rat adrenal zona glomerulosa, acting through an endothelin A receptor coupled with protein kinase C- and tyrosine kinase-dependent signaling pathways. Endocrinology. 138:1997;2333-2338.
41. Rossi GP, Belloni AS, Nussdorfer GG, Pessina AC. Endothelin-1 and the adrenal gland. J Cardiovasc Pharmacol 1999; (in press).
42. Nussdorfer GG, Rossi GP, Malendowicz LK, Mazzocchi G. The autocrine-paracrine role of endothelin system in the physiology and pathology of steroid secreting tissues in the paracrine control of the secretion and growth of the adrenal cortex. Pharmacol Rev 1999; (in press).
43. Yang Z.H., Richard V., von Segesser L., et al. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? Circulation. 82:1990;188-195.
44. Whitworth C.E., Veniant M.M., Firth J.D., Cumming A.D., Mullins J.J. Endothelin in the kidney in malignant phase hypertension. Hypertension. 26:1995;925-931.
45. Clozel M., Breu V., Gray G.A., et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther. 270:1994;228-235.
46. Balakrishnan S.M., Wang H.D., Gopalakrishnan V., Wilson T.W., McNeill J.R. Effect of an endothelin antagonist on hemodynamic responses to angiotensin II. Hypertension. 28:1996;806-809.
47. Rajagopalan S., Laursen J.B., Borthayre A., et al. Role for endothelin-1 in angiotensin II-mediated hypertension. Hypertension. 30:1997;29-34.
48. Moreau P., d'Uscio L.V., Shaw S., et al. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation. 96:1997;1593-1597.
49. A receptors for endothelin regulation. Biochem Biophys Res Commun. 238:1997;861-865.
50. d'Uscio L.V., Moreau P., Shaw S., et al. Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension. Hypertension. 29:1997;435-441.
51. Herizi A., Jover B., Bouriquet N., Mimran A. Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension. 31:1998;10-14.
52. Massart P.E., Hodeige D.G., Van Mechelen H., et al. Angiotensin II and endothelin-1 receptor antagonists have cumulative hypotensive effects in canine Page hypertension. Circulation. 84:1991;2476-2484.
53. Gardiner S.M., March J.E., Kemp P.A., Mullins J.J., Bennett T. Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats. Br J Pharmacol. 116:1995;2237-2244.
54. Ganten D., Lindpaintner K., Ganten U., et al. Transgenic rats: new animal models in hypertension research. Invited lecture. Hypertension. 17:1991;843-855.
55. Cargnelli G., Rossi G.P., Pessina A.C., et al. Changes of blood pressure and aortic strip contractile responses to ET-1 of heterozygous female transgenic rats, TGR(mRen2)27. Pharmacol Res. 37:1998;207-211.
56. Gardiner S.M., Kemp P.A., March J.E., Bennett T. Enhanced involvement of endothelin in the haemodynamic sequelae of endotoxaemia in conscious, hypertensive, transgenic ((mRen-2)27) rats. Br J Pharmacol. 123:1998;1403-1408.
57. Schricker K., Scholz H., Hamann M., et al. Role of endogenous endothelins in the renin system of normal and two-kidney, one clip rats. Hypertension. 25:1995;1025-1029.
58. Schiffrin E.L. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension. 25:1995;1135-1143.
59. Lariviere R., Day R., Schiffrin E.L. Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 21:1993;916-920.
60. Lariviere R., Deng L.Y., Day R., et al. Increased endothelin-1 gene expression in the endothelium of coronary arteries and endocardium in the DOCA-salt hypertensive rat. J Mol Cell Cardiol. 27:1995;2123-2131.
61. B endothelin receptor antagonist bosentan. Can J Physiol Pharmacol. 73:1995;390-398.
62. Day R., Lariviere R., Schiffrin E.L. In situ hybridization shows increased endothelin-1 mRNA levels in endothelial cells of blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Am J Hypertens. 8:1995;294-300.
63. Li J.S., Lariviere R., Schiffrin E.L. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension. 24:1994;183-188.
64. Barton M., d'Uscio L.V., Shaw S., et al. ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension. 31:1998;499-504.
65. Ferri C., Bellini C., Desideri G., et al. Elevated plasma and urinary endothelin-1 levels in human in salt-sensitive hypertension. Clin Sci (Colch). 93:1996;35-41.
66. Loffler BM. Endothelin converting enzyme inhibitors: current status and perspectives. J Cardiovasc Pharmacol 1999; (in press):
67. Kiowski W., Sutsch G., Hunziker P., et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736.
68. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.